Scientific Advisory Board

Ronald Levy, M.D.

Stanford University

Dr. Levy is currently the Robert K. and Helen K. Summy Professor and Director of the Lymphoma Program at Stanford University School of Medicine. He is an elected member of the National Academy of Sciences and the National Academy of Medicine. He received his bachelor’s degree from Harvard University his M.D. from Stanford University, and completed his internship and residency in internal medicine at Massachusetts General Hospital. Dr. Levy also served as a clinical associate at the Immunology Branch of the National Cancer Institute, followed by one year fellowship at Stanford and two years at the Weizmann Institute of Science. His ground-breaking research on the study of lymphomas produced the first successfully treatment of cancer with a monoclonal anti-idiotypic antibody, and paved the way for the development of rituximab (Rituxan®) for the treatment of B-cell lymphoma. Dr. Levy shared the first Armand Hammer Award for Cancer Research, and was later awarded the Ciba-Geigy/Drew Award in Biomedical Research, the American Society of Clinical Oncology Karnofsky Award, the General Motors Charles Kettering Prize, the Key to the Cure Award by the Cure for Lymphoma Foundation, the Medal of Honor by the American Cancer Society, the Evelyn Hoffman Memorial Award by the Lymphoma Research Foundation of America, Damashek Prize from the American Society of Hematology and, the King Faisal International Prize in Medicine. Dr. Levy has published over 300 articles in the fields of oncology and immunology.

James R. Swartz, Sc.D.

Stanford University

Prof. Swartz, a leading expert in the field of cell-free protein synthesis, is a director and founder of Sutro Biopharma. He holds the James H. Clark Professorship in the School of Engineering at Stanford University and is a professor in the departments of bioengineering and chemical engineering. Prof. Swartz is a member of the National Academy of Engineering with over twenty years of industrial experience at Eli Lilly and Genentech prior to joining Stanford in 1998. He received his undergraduate degree in chemical engineering from the South Dakota School of Mines and his graduate degree from the Massachusetts Institute of Technology. Prof. Swartz is an author and a co-author on numerous scientific publications dealing with protein expression and advancement of cell-free protein production technology.